Unknown

Dataset Information

0

Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.


ABSTRACT: Genetic risk factors for chemotherapy-induced peripheral neuropathy (CIPN), a major dose-limiting side-effect of paclitaxel, are not well understood. We performed a genome-wide association study (GWAS) in 183 paclitaxel-treated patients to identify genetic loci associated with CIPN assessed via comprehensive neuropathy phenotyping tools (patient-reported, clinical and neurological grading scales). Bioinformatic analyses including pathway enrichment and polygenic risk score analysis were used to identify mechanistic pathways of interest. In total, 77% of the cohort were classified with CIPN (n = 139), with moderate/severe neuropathy in 36%. GWAS was undertaken separately for the three measures of CIPN. GWAS of patient-reported CIPN identified 4 chromosomal regions that exceeded genome-wide significance (rs9846958, chromosome 3; rs117158921, chromosome 18; rs4560447, chromosome 4; rs200091415, chromosome 10). rs4560447 is located within a protein-coding gene, LIMCH1, associated with actin and neural development and expressed in the dorsal root ganglia (DRG). There were additional risk loci that exceeded the statistical threshold for suggestive genome-wide association (P < 1 × 10-5) for all measures. A polygenic risk score calculated from the top 46 ranked SNPs was highly correlated with patient-reported CIPN (r2 = 0.53; P = 1.54 × 10-35). Overlap analysis was performed to identify 3338 genes which were in common between the patient-reported CIPN, neurological grading scale and clinical grading scale GWAS. The common gene set was subsequently analysed for enrichment of gene ontology (GO) and Reactome pathways, identifying a number of pathways, including the axon development pathway (GO:0061564; P = 1.78 × 10-6) and neuronal system (R-HSA-112316; adjusted P = 3.33 × 10-7). Our findings highlight the potential role of axon development and regeneration pathways in paclitaxel-induced CIPN.

SUBMITTER: Hooshmand K 

PROVIDER: S-EPMC9724416 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study.

Hooshmand Kosar K   Goldstein David D   Timmins Hannah C HC   Li Tiffany T   Harrison Michelle M   Friedlander Michael L ML   Lewis Craig R CR   Lees Justin G JG   Moalem-Taylor Gila G   Guennewig Boris B   Park Susanna B SB   Kwok John B JB  

Journal of translational medicine 20221206 1


<h4>Background</h4>Genetic risk factors for chemotherapy-induced peripheral neuropathy (CIPN), a major dose-limiting side-effect of paclitaxel, are not well understood.<h4>Methods</h4>We performed a genome-wide association study (GWAS) in 183 paclitaxel-treated patients to identify genetic loci associated with CIPN assessed via comprehensive neuropathy phenotyping tools (patient-reported, clinical and neurological grading scales). Bioinformatic analyses including pathway enrichment and polygenic  ...[more]

Similar Datasets

| S-EPMC3445665 | biostudies-literature
| S-EPMC3549006 | biostudies-literature
| S-EPMC4592389 | biostudies-literature
| S-EPMC6173931 | biostudies-literature
| S-EPMC4717479 | biostudies-literature
| S-EPMC4111770 | biostudies-literature
2016-06-01 | GSE66903 | GEO
| S-EPMC6094450 | biostudies-literature
| S-EPMC3475250 | biostudies-literature
| S-EPMC5010494 | biostudies-literature